Report of Foreign Issuer (6-k)
August 29 2019 - 8:32AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of
1934
For the month of August 2019
Commission File Number: 001-37643
KITOV PHARMA LTD.
(Translation of registrant’s name
into English)
One Azrieli Center, Round Tower,
132 Menachem Begin Road, Tel Aviv 6701101,
Israel
(Address of principal executive offices)
Indicate by check mark
whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒
Form 40-F ☐
Indicate by check mark
if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark
if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
Kitov Pharma Ltd.
(the “Company” or the “Registrant”) is announcing that on August 29, 2019, the Company issued a press release
“Kitov Pharma to Present New Data on NT-219 Targeting Cancer Drug Resistance at the AACR Pancreatic Cancer: Advances in
Science and Clinical Care Conference,” which is attached hereto as Exhibit 99.1.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
KITOV PHARMA LTD.
|
|
|
|
August 29, 2019
|
By:
|
/s/ Isaac Israel
|
|
|
Isaac Israel
|
|
|
CEO & Director
|
2
Kitov Pharma (NASDAQ:KTOV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kitov Pharma (NASDAQ:KTOV)
Historical Stock Chart
From Apr 2023 to Apr 2024